Patents by Inventor Ronald Magolda

Ronald Magolda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phosphate Derivatives of Substituted Benzoxazoles
    Publication number: 20110212923
    Abstract: The present invention relates to phosphate derivatives of estrogen receptor beta agonists, compositions thereof, preparations thereof, and uses thereof. Formula (I).
    Type: Application
    Filed: February 6, 2009
    Publication date: September 1, 2011
    Inventors: Reinhardt Baudy, Eugene J. Trybulski, Ronald Magolda, Diane Schneider, Gulnaz Khafizova, Mahdi B. Fawzi, Cuijian Yang
  • Antibodies to aggrecan-degrading metalloprotease and diagnostic methods using same
    Patent number: 7049412
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: May 23, 2006
    Assignee: Bristol-Myers Squibb Pharma Comp.
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
  • Aggrecan degrading metallo proteases
    Patent number: 6753176
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: June 22, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
  • Aggrecan degrading metallo proteases
    Publication number: 20030108998
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Application
    Filed: September 19, 2002
    Publication date: June 12, 2003
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
  • Nucleic acids encoding aggrecan degrading metallo proteases
    Patent number: 6521436
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: February 18, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
  • Aggrecan degrading metallo proteases
    Patent number: 6451575
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: September 17, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang